Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Orplatna Needs Overall Survival Data For Prostate Cancer Indication – ODAC

Executive Summary

Progression-free survival data for GPC Biotech's Orplatna are flawed and do not justify accelerated approval of the drug, FDA's Oncologic Drugs Advisory Committee concluded July 24
Advertisement

Related Content

FDA Cancer Endpoint Guidance Abandons Placebos, Moves Beyond Survival
Patient-Reported Outcomes Guidance Needs Flexibility, Industry Tells FDA
Patient-Reported Outcomes Guidance Needs Flexibility, Industry Tells FDA
Advertisement
UsernamePublicRestriction

Register

PS048628

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel